Effectiveness of ethinyl oestradiol /cyproterone acetate and ethinyl oestradiol/ desogestrel with or without low-dose metformin on perceived health-related quality of life in hirsute women with polycystic ovary disease: A randomised, double-blind, placebo-controlled study
Archives of Psychiatry and Mental Health · 2019
DOI: 10.29328/journal.apmh.1001007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Psychiatry and Mental Health, 2019. Verfasst von Sanjeewani Fonseka und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Polycystic ovary disease (PCOD) is an endocrine disorder. It leads to menstrual disturbances, infertility, obesity and dermatological manifestations such as hirsutism and acne which leads to impaired health-related quality of life (QOL).
Aims
To evaluate the perceived health related QOL in patients with PCOD treated with ethinyl oestradiol (35µg)/cyproterone acetate (2 mg) (EE/CPA) and ethinyl oestradiol (20 µg)/ desogestrel (0.15mg) (EE/DES) alone and in combination with low-dose metformin.
Methods
A total of 117 patients with PCOD diagnosed according to Rotterdam Consensus Criteria 2003 with a hirsutism score of 8 or more according to modified Ferriman-Gallway Score (mFGS) were randomised to receive one of four drug combinations (arm A – EE/CPA, arm B- EE/DES, arm C- EE/CPA plus metformin, arm D- EE/DES plus metformin). The outcomes assessed were body mass index (BMI), hirsutism (using mFGS) and health-related QOL (Polycystic Ovary Syndrome Health- Related quality of life Questionnaire (PCOSQ) and a Visual Analog Scale (VAS) score) at baseline and 12 months after treatment.
Results
PCOSQ score in relation to the hirsutism, emotions, menstruation, obesity, infertility and VAS score in relation to hirsutism and obesity had improved at the end of 12 months (p< 0.001) in all treatment arms. There was no difference between treatment arms in all measured outcomes at baseline and at the end of 12 months.
Conclusion
Treatment with EE/CPA and EE/DES is associated with an improvement in perceived QOL in patients with PCOD. The addition of low-dose metformin did not have a significant benefit.
Zitieren
APA
Fonseka, S., Subhani, B., Alahakoon, V., Wijeyaratne, C., Gawarammana, I., Kalupahana, N., Ratnatunga, N., Rosairo, S., & Kumarasiri, P. (2019). Effectiveness of ethinyl oestradiol /cyproterone acetate and ethinyl oestradiol/ desogestrel with or without low-dose metformin on perceived health-related quality of life in hirsute women with polycystic ovary disease: A randomised, double-blind, placebo-controlled study. Archives of Psychiatry and Mental Health. https://doi.org/10.29328/journal.apmh.1001007
Vancouver
Fonseka S, Subhani B, Alahakoon V, Wijeyaratne C, Gawarammana I, Kalupahana N, et al. Effectiveness of ethinyl oestradiol /cyproterone acetate and ethinyl oestradiol/ desogestrel with or without low-dose metformin on perceived health-related quality of life in hirsute women with polycystic ovary disease: A randomised, double-blind, placebo-controlled study. Archives of Psychiatry and Mental Health. 2019. doi:10.29328/journal.apmh.1001007
BibTeX
@article{Fonseka2019,
author = {Fonseka, Sanjeewani and Subhani, B and Alahakoon, V and Wijeyaratne, CN and Gawarammana, IB and Kalupahana, NS and Ratnatunga, N and Rosairo, S and Kumarasiri, PVR},
title = {Effectiveness of ethinyl oestradiol /cyproterone acetate and ethinyl oestradiol/ desogestrel with or without low-dose metformin on perceived health-related quality of life in hirsute women with polycystic ovary disease: A randomised, double-blind, placebo-controlled study},
journal = {Archives of Psychiatry and Mental Health},
year = {2019},
doi = {10.29328/journal.apmh.1001007}
}
EUVIMED